TriangleBCB-276 (NCT07680439)
BCB-276 trial for Diffuse Intrinsic Pontine Glioma (NCT07680439). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged 1–26 with nonmetastatic diffuse intrinsic pontine glioma (DIPG), weighing at least 10 kilograms, enrolled within six weeks after initial radiation. Prior treatment is limited to radiation with or without temozolomide.
The idea: collect white blood cells and modify patients’ own T cells to recognize and attack B7-H3-bearing tumor cells. BCB-276 is delivered through a brain-fluid catheter every two weeks, for up to 15 doses. Researchers study survival and safety.
This phase 2 study plans 75 patients. BrainChild Bio sponsors it; three US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.